Following women with neuroimmune diseases through pregnancy and after delivery
Follows women of reproductive age with neuroimmune diseases during pregnancy.
Plain-language title generated from the registry record
Registry title: Cohort Study on Neuroimmune Diseases in the Reproductive Age
Key facts
- Where
- Guangzhou, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women of childbearing age with a confirmed neuroimmune disease, and for healthy women of the same age as a comparison group.
- Age
- 20 to 55 years
- Sex
- Women only
- Disease stage
- A confirmed diagnosis of NMOSD, multiple sclerosis, autoimmune encephalitis, myasthenia gravis, Guillain-Barré syndrome, or MOGAD. The healthy group has no neuroimmune disease.
Main reasons for not taking part
- Diagnosis is undetermined or unconfirmed
- Personal information is incomplete and cannot be obtained through follow-up
- Withdrew from the study or took back consent
- Healthy group: has a neuroimmune-related disorder
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 55 years old?
Source: NCT07653984, who can take part
Where in China
- The Third Affiliated Hospital,Sun Yat-Sen UniversityGuangzhou, ChinaContact: Wei Qiu, Ph.DTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Third Affiliated Hospital, Sun Yat-Sen University
- Trial code
- NCT07653984
- Record updated
- 17 June 2026
- Original description
Neuroimmune diseases are more prevalent among women of reproductive age. Studies have shown that neuroimmune diseases may impact fertility. Therefore, effective management of neuroimmune diseases during pregnancy is particularly important. This study included a follow-up period of up to five years in patients with pregnancy-associated neuroimmune disorders. Data collected included relapse frequency, symptomatology, imaging findings, treatment regimens, peripheral blood profiles, EDSS scores, and MRI results. In addition, maternal drug concentrations, postpartum relapse rates, and neonatal development were monitored after delivery. Following the successful completion of the five-year follow-up, the research team plans to continue the prospective epidemiological study with ten-year follow-up phases. The aim of this study is to generate detailed clinical data on pregnancy-associated autoimmune diseases and to equip clinicians with evidence-based strategies for optimizing disease management during the reproductive age.Read full original descriptionShow less
Cohort Study on Neuroimmune Diseases in the Reproductive Age
Neuroimmune diseases are more prevalent among women of reproductive age. Studies have shown that neuroimmune diseases may impact fertility. Therefore, effective management of neuroimmune diseases during pregnancy is particularly important. This study included a follow-up period of up to five years in patients with pregnancy-associated neuroimmune disorders. Data collected included relapse frequency, symptomatology, imaging findings, treatment regimens, peripheral blood profiles, EDSS scores, and MRI results. In addition, maternal drug concentrations, postpartum relapse rates, and neonatal development were monitored after delivery. Following the successful completion of the five-year follow-up, the research team plans to continue the prospective epidemiological study with ten-year follow-up phases. The aim of this study is to generate detailed clinical data on pregnancy-associated autoimmune diseases and to equip clinicians with evidence-based strategies for optimizing disease management during the reproductive age.
Inclusion: Patient Group: A total of fifty participants are expected to be enrolled; Women aged 20-55 years with childbearing potential; Voluntary informed consent; Availability of complete personal information; A confirmed diagnosis of neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS), autoimmune encephalitis, myasthenia gravis, Guillain-Barré syndrome, or myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD); Healthy Control Group: A total of fifty healthy women are expected to be included; Age- and sex-matched women of childbearing age with plans for pregnancy; Voluntary informed consent; Availability of complete personal information.
Exclusion: Individuals diagnosed with neuroimmune-related disorders; Patient Group:; Patients with an undetermined or unconfirmed diagnosis; Incomplete personal information that cannot be obtained through follow-up; Participants who voluntarily withdrew from the study and revoked informed consent; Healthy Control Group:; Incomplete personal information that cannot be obtained through follow-up; Participants who voluntarily withdrew from the study and revoked informed consent.